Jennifer Jackson

ORCID: 0000-0001-5998-1999
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Molecular Biology Techniques and Applications
  • RNA modifications and cancer
  • Genetic factors in colorectal cancer
  • Renal cell carcinoma treatment
  • CAR-T cell therapy research
  • Ferroptosis and cancer prognosis
  • Lung Cancer Research Studies
  • Liver Disease Diagnosis and Treatment
  • Biochemical Analysis and Sensing Techniques
  • Biochemical and Molecular Research
  • Cancer Cells and Metastasis
  • Cancer Research and Treatments
  • Gene expression and cancer classification
  • Alcohol Consumption and Health Effects
  • Bladder and Urothelial Cancer Treatments
  • Urinary and Genital Oncology Studies
  • Macrophage Migration Inhibitory Factor
  • Pancreatic and Hepatic Oncology Research
  • Cellular Mechanics and Interactions
  • Lymphoma Diagnosis and Treatment
  • Fatty Acid Research and Health
  • Electrowetting and Microfluidic Technologies

LabCorp (United States)
2023-2025

The University of Texas MD Anderson Cancer Center
2024

Duke University Hospital
2024

Human Genome Sciences (United States)
2019-2023

Pennsylvania State University
2021-2022

Certis USA (United States)
2022

Ono Pharmaceutical (United States)
2008-2022

Research & Development Institute
2022

Boston Medical Center
2017-2019

Boston University
2016-2019

Detection of cell-free DNA in liquid biopsies offers great potential for use non-invasive prenatal testing and as a cancer biomarker. Fetal tumor fractions however can be extremely low these samples ultra-sensitive methods are required their detection. Here, we report an simple fast method introduction barcodes into libraries made from 5 ng DNA. Barcoded adapter primers designed with oligonucleotide hairpin structure to protect the molecular during first rounds polymerase chain reaction...

10.1093/nar/gkw224 article EN cc-by-nc Nucleic Acids Research 2016-04-07

Background Immune checkpoint inhibitors (ICIs) have expanded treatment options for metastatic renal cell carcinoma (mRCC); however, there are limited predictive biomarkers response to ICIs in this indication, with programmed death-ligand 1 (PD-L1) status demonstrating little utility mRCC. While of ICI other tumor types, the mutation burden (TMB) mRCC is unclear. Here, we assess TMB, loss antigen presentation genes and PD-L1 correlated outcomes Methods Tumor samples from 34 patients treated...

10.1136/jitc-2019-000319 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2020-03-01

Therapy resistance and associated liver disease make hepatocellular carcinomas (HCC) difficult to treat with traditional cytotoxic therapies, whereas newer targeted approaches offer only modest survival benefit. We focused on DNA-dependent protein kinase, DNA-PKcs, encoded by PRKDC central DNA damage repair nonhomologous end joining. Our aim was explore its roles in hepatocarcinogenesis as a novel therapeutic candidate.

10.1158/1078-0432.ccr-14-0842 article EN Clinical Cancer Research 2014-12-06

<i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A Review</i> : Cancer cell growth releases molecular biomarkers into blood that can be useful in diagnostic tests, e.g., serum biomarkers. The use of involves an invasive sample collection procedure. Human exhaled breath is potentially a noninvasive source cancer biomarker compounds. A few analysis studies have reported sensitivities > 90% and specificities 80% using suite to differentiate subjects...

10.1109/jsen.2009.2035669 article EN IEEE Sensors Journal 2010-01-01

Abstract Background Patients with B-cell lymphoma and acute lymphoblastic leukemia (ALL) who receive chimeric antigen receptor T-cell (CAR-T) therapy may experience clinically significant cytomegalovirus infection (CS-CMVi). However, risk factors for CS-CMVi are not well defined. The aims of our study were to identify the association between nonrelapse mortality (NRM) in ALL patients after CAR-T therapy. Methods We performed a retrospective single-center cohort analysis recipients January...

10.1093/ofid/ofae422 article EN cc-by Open Forum Infectious Diseases 2024-07-17
Dariush Mozaffarian Kevin C. Maki Harold Bays Fernando Aguilera Glenn Gould and 95 more Robert A. Hegele Patrick M. Moriarty Jennifer G. Robinson Peilin Shi Josefina F. Tur Jean‐François Lapointe Sarya Aziz Pierre Lemieux Tao Hao Lubna Mirza Gaylon Kipp Wentworth Jarrett Raymond Little Hipolito Mariano Nagapradeep Nagajothi Kevin J. Bender Brian Everhart Syed T. Rahman Lisa Usdan David A. Larsen John McGettigan Roohi Faiyaz J. Foucauld Calvin Higgins Fadi Chalhoub William D. Freeman Steven Corse Stephen D. Miller Amol Malanakar Michael Reschak Mahendra Jain Adline Ghazi Nizar Daboul Natalia Hegedosh Mark McKenzie Marina Raikhel John H. Dodd Leonard Dunn Stephan Jannach S Sojka H Sherman James Diener Barry Horowitz Marian Shaw Walter Pharr John David Lentx Enrique Hanabergh R Miller Andres Patron John Agaiby Michael Feldman Gilbert Ledesma Lidia Rosa Bermudez Preetham Jetty Giselle Debs-Perez Aslam Loya David Butuk Amy Cullen Chris Recknor Lon Lynn Lisa Connery Pedro Ylisastigui Randall Huling Marianela De La Portilla Humberto Cruz Roberto Sotolongo Isaac Dor Raul Ebran-Gonzalez Samuel Lederman Omar Benitez James C. Cain Vivek Awasty Cindy Martinez R Hernandez Michael Dao Antonio Terrelonge Jennifer Jackson Robert Busch Sameul Mujica Trenche Kim Barbel-Johnson Carlos Ince Bernard Garcia Colby Grossman George Mitchell Cornett Faisal Latif Amer Al‐Karadsheh Robinson Koilpillai Jorge Alvarez-Moreno Krista Preston David C. Wright J.W. Martijn van Eck Suzanne Fussell Javier Reyna Royce Keith Solano Joseph Raoof

<h3>Importance</h3> Intense interest exists in novel ω-3 formulations with high bioavailability to reduce blood triglyceride (TG) levels. <h3>Objective</h3> To determine the phase 3 efficacy and safety of a naturally derived krill oil eicosapentaenoic acid docosahexaenoic as both phospholipid esters (PLs) free fatty acids (FFAs) (ω-3–PL/FFA [CaPre]), measured by fasting TG levels other lipid parameters severe hypertriglyceridemia. <h3>Design, Setting, Participants</h3> This study pooled...

10.1001/jamanetworkopen.2021.41898 article EN cc-by-nc-nd JAMA Network Open 2022-01-06

ABSTRACT Skeletal muscle is primarily composed of large myofibers containing thousands post-mitotic nuclei distributed throughout a common cytoplasm. Protein production and localization in specialized myofiber regions crucial for function. Myonuclei differ transcriptional activity protein accumulation, but how these differences among sharing cytoplasm are achieved unknown. Regulated nuclear import proteins one potential mechanism regulating transcription spatially temporally individual...

10.1242/jcs.207670 article EN publisher-specific-oa Journal of Cell Science 2018-02-01

The interaction between water and surfaces is observed in our daily lives used laboratories to study materials properties, such as interfacial tension. Making the connection fundamental scientific phenomena everyday observations a powerful method of highlighting importance relevance science K–12 population. Typically, expensive equipment, dedicated contact angle goniometers, observe how interacts with materials. Obtaining laboratory-grade equipment for classroom not only difficult but also...

10.1021/acs.jchemed.1c00098 article EN cc-by-nc-nd Journal of Chemical Education 2021-05-12

The method currently most used for probeset detection calls on Affymetrix GeneChipreg Human Genome Arrays is provided as part of the MAS5 software. MAS uses Wilcoxon statistics determining presence-absence (MAS-P/A) calls. However, MAS-P/A only usable with processing, which requires use both perfect match (PM) and mismatch (MM) probe data in order to call resulting present or absent. A considerable amount recent research has convincingly shown that using MM gene expression analysis may be...

10.1109/bibe.2007.4375552 article EN 2007-10-01

Protocols measuring cough sensitivity can vary in terms of nebuliser, tussive agent, single and dose response. A definitive method for needs to be established.The ERS guidelines recommend the KoKo DigiDoser (KD) delivery system. Study aim, was compare reproducibility this citric acid (CA) challenge previously established Mefar dosimeter (MD) protocol.39 (female 26) volunteers mean age (40.4 yrs) were randomised either KD or MD. Intra-day inter-day compared.We calculated concentration evoking...

10.1186/1745-9974-6-8 article EN cc-by Cough 2010-01-01

Genomic tumor profiling by next-generation sequencing (NGS) allows for large-scale testing to inform targeted cancer therapies and immunotherapies, identify patients clinical trials. These tests are often underutilized in with late-stage solid tumors typically performed centralized specialty laboratories, thereby limiting access these complex tests. Personal Genome Diagnostics Inc., elio tissue complete NGS solution is a comprehensive DNA-to-report kitted assay bioinformatics solution....

10.1016/j.jmoldx.2021.07.004 article EN cc-by-nc-nd Journal of Molecular Diagnostics 2021-07-24

Next-generation sequencing (NGS) is currently widely used for biomarker studies and molecular profiling to identify concurrent alterations that can lead the better characterization of a tumor's landscape. However, further evaluation technical aspects related detection gene rearrangements copy number warranted. There were 12 ALK rearrangement-positive tumor specimens from patients with non-small cell lung cancer (NSCLC) previously detected via fluorescence in situ hybridization (FISH),...

10.3389/fonc.2023.1225646 article EN cc-by Frontiers in Oncology 2023-10-20

Younger patients with non-small cell lung cancer (NSCLC) (<50 years) represent a significant patient population distinct clinicopathological features and enriched targetable genomic alterations compared to older patients. However, previous studies of younger NSCLC suffer from inconsistent findings, few have incorporated sex into their analyses, targeting age-related differences in the tumor immune microenvironment are lacking.

10.3389/fimmu.2024.1413956 article EN cc-by Frontiers in Immunology 2024-06-21

Genomic profiling is critical for precision oncology to guide treatment decisions. Liquid biopsy testing a complementary approach tissue testing, particularly when not readily available. The Labcorp Plasma Focus test circulating cell-free DNA genomic that identifies actionable variants in solid cancers, including non-small-cell lung, colorectal, melanoma, breast, esophageal, gastroesophageal junction, and gastric cancers. This study highlights the analytical validation of test, accuracy...

10.1016/j.jmoldx.2023.03.008 article EN cc-by-nc-nd Journal of Molecular Diagnostics 2023-04-15

589 Background: ICIs have revolutionized treatment for mRCC; however there are limited predictive biomarkers response to ICIs. PD-L1 status is still controversial demonstrating little utility in mRCC. TMB melanoma and non-small cell lung cancer (NSCLC), but has not been validated Here, we assess the correlations between with outcomes ICI Methods: 34 patients (pts) mRCC who had previously received therapy at Duke Cancer Institute were identified. Tumor samples retrospectively evaluated using...

10.1200/jco.2019.37.7_suppl.589 article EN Journal of Clinical Oncology 2019-03-01

Calcineurin is a ubiquitously expressed calcium-dependent phosphatase that inhibited by the immunosuppressant drugs cyclosporine and tacrolimus. Measuring calcineurin activity in transplant patients has been complicated lack of consistent correlation between drug level enzyme activity, particularly with chronic use. Data from mice lacking CnAα or CnAβ isoform catalytic subunit demonstrate loss results immunosuppression, whereas does not. As such, methods to examine may be more clinically...

10.1097/tp.0b013e31829acb64 article EN Transplantation 2013-07-04

2587 Background: Ipilimumab, a fully-human monoclonal antibody against CTLA-4, has demonstrated significant improvement in overall survival (OS) previously treated advanced melanoma patients. The BRAF inhibitor, RG7204 (also known as PLX4032) shown high objective response rates (up to 78%) patients harbouring the BRAFV600E mutation but not without (e.g. wild-type BRAF). As an immune potentiator, it is likely that ipilimumab acts independently of kinase mutations and similar activity positive...

10.1200/jco.2011.29.15_suppl.2587 article EN Journal of Clinical Oncology 2011-05-20
Coming Soon ...